Opinion on Drug Delivery

Published within

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Inex/GSK: the growing importance of drug delivery

GSK will foot the bill for Inex's development work. In a market where drug delivery is becoming as important as the compound itself, the deal represents a good chance for GSK to boost the sales and life expectancy of its drug. Inex, meanwhile, should gain significant opportunities by partnering with a leading pharmaceutical company.

Published By Datamonitor
26 Nov 2001
CommentWire
CommentWire

ID Biomedical: prevention is better than cure

If ID's Streptococcus vaccine proves to be effective, it has a strong chance of commercial success. There is a strong opportunity to develop vaccines for bacterial disease, as vaccination is considered preferable to antibiotic treatment. ID is at a particular advantage in this area, due to its Proteosomes nasal drug delivery technology.

Published By Datamonitor
16 Apr 2002
Expert View
Expert View

Hypertension: ALLHAT results threaten growth of the anti-hypertensives market - or do they?

Following the long awaited results from the ALLHAT trial, investigators have concluded that genericized diuretics and not newer agents should be the first line therapy in the treatment of hypertension. Datamonitor investigates suggestions that the trial design was flawed, and how the pharmaceuticals industry might counter the trial results.

Published By Datamonitor
09 Jan 2003
Expert View
Expert View

How can vaccine companies inoculate themselves?

The vaccine market is changing dramatically, thanks to regulatory moves and new technologies. Pharma companies that produce vaccines need to rethink their strategy if they are to maintain and grow their market share. Technology will be the key to success in the new-look vaccine market - but how can companies decide which technologies they should focus on?

Published By Datamonitor
30 Nov 2001
Expert View
Expert View

Hormonal Cancers: Key drivers in a market of change

Four major brands, TAP's Lupron, AstraZeneca's Zoladex, Nolvadex and Casodex, account for 49% of the total value of the anti-hormonals market at present. The loss of patent protection for these compounds will lead to an increase in generic drugs and therefore influence the rate of expansion of the market. Datamonitor examines how the drug companies will attempt to maintain their market position.<BR />

Published By Datamonitor
31 Jan 2003
CommentWire
CommentWire

HIV therapeutics: the untapped market

A significant proportion of the HIV and AIDS population remains untreated and this has led to an increased level of untapped potential in the HIV therapeutic market. Manufacturers have historically focused on treatment for existing patients. However, by taking steps to improve patient access to diagnosis and treatment, the HIV therapeutic market could lift its value considerably.

Published By Datamonitor
29 Oct 2003
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
CommentWire
CommentWire

HIV drugs: patent disputes escalate

Published By Datamonitor
28 Aug 2001
CommentWire
CommentWire

GW Pharmaceuticals: high expectations for cannabis drug

GW Pharmaceuticals [GWP.L] and Bayer Healthcare [BAY.F] have submitted a New Drug Submission for Sativex, a cannabis-based medicine for the symptomatic treatment of multiple sclerosis (MS) and neuropathic pain, to Health Canada. This move will help generate optimism regarding Sativex, offering renewed hope for manufacturers and patients alike.

Published By Datamonitor
13 May 2004
CommentWire
CommentWire

Guidant/Cook: competitors in collaboration

Published By Datamonitor
24 Aug 2001

« | ... | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ... | » »|

No help is available.